Back To Search Instructions
Protocols
10 protocols meet the specified criteria
Disease Site: Non-Hodgkin's Lymphoma
Protocol No.TitleStatus
0500000226Arizona Lymphoid Tissue and Blood Repository (ALTBR)Open
0900000967Lymphoma Outcomes and Epidemiological DatabaseOpen
1100000610A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications (10-CBA)Open
1602386062A Phase Ib/II Study Evaluating The Safety And Efficacy Of Obinutuzumab In Combination With Polatuzumab Vedotin And Venetoclax In Patients With Relapsed Or Refractory Follicular Lymphoma And Rituximab In Combination With Polatuzumab Vedotin And Venetoclax In Patients With Relapsed Or Refractory Diffuse Large B-Cell LymphomaOpen
1606616633Phase Ib Trial of Pembrolizumab (MK-3475) in Combination with Dinaciclib (MK-7965) in Subjects with Hematologic Malignancies (KEYNOTE-155)Open
1606619215An Open-Label, Phase I/II, Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients with Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma and in Combination with Endocrine Therapy in Patients with Locally Advanced or Metastatic Hormone Receptor-Positive Breast CancerOpen
1607710095Impact of stem cell transplantation in first complete remission for patients with double hit lymphomaOpen
1609876907A Phase I/II Study of Haploidentical Bone Marrow Transplant with Post-Transplant Cyclophosphamide and/or BendamustineOpen
1611031060A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of TherapyOpen
1612098443An Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize theEffects of a Moderate CYP3A Inhibitor on the Pharmacokinetics of Tazemetostat (EPZ-6438) (Part A), the Effects of Tazemetostat on the Pharmacokinetics of CYP2C8 and CYP2C19 Substrates, and the Effect of Increased Gastric pH on the Pharmacokinetics of Tazemetostat (Part B) in Subjects with B-cell LymphomasOpen